Related Experiment Video

Updated: Aug 7, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

704

Pharmacologic therapy among patients with type 2 diabetes mellitus admitted to the cardiology service

Evelyn Lesiawan1, Thomas Seaton1, Jocelyne Benatar1

  • 1Green Lane Cardiovascular Service, Auckland City Hospital, 2 Park Road, Auckland.

The New Zealand Medical Journal
|March 9, 2023
PubMed

Insights

Many patients with type 2 diabetes admitted to cardiology have poor glycemic control. Empagliflozin could benefit half of these patients, improving cardiovascular and renal outcomes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Diabetes Management

Background:

  • Type 2 diabetes is a significant comorbidity in cardiology patients.
  • Optimal diabetes management is crucial for improving cardiovascular and renal outcomes.
  • Empagliflozin is a medication that offers benefits for both diabetes and cardiovascular health.

Purpose of the Study:

  • To review diabetes management in type 2 diabetes patients admitted to cardiology.
  • To assess the potential benefit of empagliflozin for these patients based on current guidelines.
  • To identify opportunities for medication optimization in this patient population.

Main Methods:

  • Retrospective audit of cardiology admissions from November 2020 to January 2021.
  • Data collection included diabetes status, HbA1c levels, and current medications.
  • Analysis focused on patient eligibility for empagliflozin.

Main Results:

  • 98 out of 449 admissions (21.8%) had type 2 diabetes.
  • 50% of patients had an HbA1c > 60 mmol/mol, indicating poor glycemic control.
  • 50% of patients met criteria for potential empagliflozin eligibility.

Conclusions:

  • A significant proportion of cardiology patients with type 2 diabetes experience suboptimal glycemic control.
  • There is a missed opportunity for medication optimization, particularly in over-represented Pacific Peoples.
  • Empagliflozin presents a targeted therapeutic option to address renal and cardiovascular risks in this cohort.
Abstract

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

242
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
323
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
21
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
250
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
18
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
802